Millions of Americans have turned to glucagon-like peptide-1 (GLP-1) drugs for weight loss, drawn by results that promise double-digit body weight reductions.
Yet prescriptions are only as effective as a patient’s ability to keep filling them, and researchers have now pinpointed a price ceiling for that ability.
The findings challenge a common assumption that higher medication costs gradually erode compliance, revealing instead a sharp financial cliff where most patients simply walk away.
Semaglutide adherence collapses once out-of-pocket costs cross $75
A University of Georgia study tracked 8,914 commercially insured adults who began taking semaglutide specifically for weight loss between June 2021 and December 2022.
More on healthcare costs:
- CMS loosens grip to let Medicare Advantage deals flow
- Medicare’s drug price rule could raise costs in 19 nations
- Medigap Plan F holders face a trap that tightens with age
Researchers sorted patients into five monthly out-of-pocket tiers, ranging from under $21 at the bottom to more than $168 at the top, the study published in JAMA Health Forum found.
Even at the lowest tier, roughly three in four patients abandoned their GLP-1 prescription within the first year of treatment. However, adherence held relatively steady across the lower cost brackets until monthly spending crossed approximately $75, at which point nonadherence rose to approximately 80%, the researchers reported.
The pattern caught lead author Eunhae Shin, an assistant professor of health policy and management at UGA’s College of Public Health, off guard. Shin expected a straightforward linear relationship between rising costs and falling adherence, but the data instead revealed a threshold effect concentrated around the $75 mark.
High-deductible plans push GLP-1 patients into the costliest tier
The lowest adherence rate in the study, roughly 17%, belonged to patients spending $168 or more each month on their GLP-1 prescription.
Patients in that group were disproportionately enrolled in high-deductible health plans and clustered in Southern states, the study noted.
Under those plan structures, patients shoulder the full cost of their medication until they meet an annual deductible that can stretch into several thousand dollars.
Plans that pair low monthly premiums with high cost-sharing create a particular affordability trap for patients on recurring prescriptions, because the out-of-pocket burden restarts every month.
“That basically means people who have employer-sponsored insurance may continue to face these financial barriers,” Shin told UGA Today.
A separate Navitus Health Solutions survey of 2,000 GLP-1 users found that 68% of respondents said cost influenced their decision to start or continue treatment, and 44% reported that expenses exceeded their initial expectations, Managed Healthcare Executive reported.
Medicare caps GLP-1 spending at $50, but commercial insurers have not followed
Federal programs have already moved to address the affordability gap for eligible Medicare enrollees, capping monthly GLP-1 out-of-pocket costs at $50 through the Medicare GLP-1 Bridge program launched in July 2026.
Commercial insurers, which cover most working-age Americans, have not adopted comparable price caps. The UGA study authors noted that commercially insured patients may continue to face cost-sharing levels their analysis links to substantially lower medication adherence.
Colin Banas, MD, chief medical officer at DrFirst, a prescribing workflow company, pointed to a similar trend in his own firm’s data. Once out-of-pocket spending crosses roughly $100, first-fill adherence for GLP-1 drugs drops significantly, Banas told Pharmaceutical Commerce in an interview.
Obesity’s chronic disease burden could offset short-term medication costs
Obesity raises the likelihood of developing heart disease, type 2 diabetes, and high blood pressure, all of which generate recurring medical expenses that can dwarf the upfront cost of a monthly GLP-1 prescription.
Unexpected emergency room visits and hospitalizations represent a significant financial risk for patients who stop treatment early.
Shin said she hopes future research can demonstrate whether sustained GLP-1 use reduces emergency department visits, hospital admissions, and total long-term spending.
If those downstream savings materialize, policymakers and insurers may find a stronger case for restructuring drug cost designs around these medications, the researcher noted.
Key data points from the UGA study
- The study analyzed 8,914 patients with continuous insurance enrollment over an 18-month period (JAMA Health Forum)
- Three in four patients stopped their GLP-1 within a year, even at the lowest out-of-pocket tier (UGA Today)
- Nonadherence rose to approximately 80% once monthly costs crossed roughly $75 (JAMA Health Forum)
- Patients paying $168 or more monthly showed just 17% adherence, the lowest in the study (JAMA Health Forum)
- Over half of patients in the highest cost tier were enrolled in high-deductible plans (AJMC)
What this means for GLP-1 patients and their coverage
The UGA findings sharpen a practical dilemma for the millions of commercially insured patients now taking or considering GLP-1 medications for weight management.
Shin’s research shows that adherence does not erode gradually with rising costs but instead collapses at a specific monthly threshold, suggesting that even modest insurance design changes could meaningfully extend treatment persistence for patients currently priced out.
Sharon Faust, PharmD, chief pharmacy officer at Navitus Health Solutions, echoed that conclusion, noting that balancing affordability and access will challenge employers, health plans, and drug manufacturers as GLP-1 use continues to grow, Managed Healthcare Executive reported.
For patients currently on GLP-1s, reviewing plan benefits, checking manufacturer discount programs, and tracking out-of-pocket spending against the $75 threshold identified in this study could help gauge whether their current coverage supports sustained treatment.
